allergic rhinitis
Conditions
Interventions
SILT group:The SLIT group was treated with sublingual dust mite drops combined with symptomatic medications.
Control group:The control group was treated only with symptomatic medications.
Sponsors
The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Individuals aged 18 to 60 years old (inclusive of 18 and 60) are eligible, regardless of gender. (2) Patients diagnosed with moderate to severe AR and having a history of perennial allergic rhinitis for at least two years. (3) Patients have positive results for dust mites and/or house dust mites in allergen testing (skin prick test or serum specific IgE test) (prick level >= ++; sIgE level >= grade 2), and it is determined through correlation judgment that dust mites are the main allergens. (4) Patients can understand and sign the informed consent form. (5) Patients can actively comply with the protocol and accept at least one year of follow-up.
Exclusion criteria
Exclusion criteria: (1) Those who were diagnosed with a history of severe asthma or had FEV1 less than 70% of the predicted value within the last 2 years before enrollment; (2) Patients with nasal septum deviation and other nasal structural abnormalities, or those with a history of nasal surgery or trauma; (3) Patients who received nasal or systemic steroid treatment within the last month before enrollment, those who received antihistamine medication within the last week, and those who received decongestants or saline nasal irrigation within the last two days; (4) Patients currently undergoing treatment with beta-blockers (including systemic and local medications) or angiotensin-converting enzyme (ACE) inhibitors; (5) Pregnant or lactating women; (6) Those who had upper respiratory tract infections within the last two weeks; those with a history of severe systemic allergic reactions, immunosuppressive diseases (such as HIV infection history), malignant tumor history, autoimmune disease history, tuberculosis history, cardiovascular dysfunction or other serious diseases of other organ systems as determined by the investigator; (7) Any other conditions assessed as not suitable for participation in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nasal mucosa ciliary transport time;Symptoms of rhinitis - Medication combination score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Analog Scale, VAS;Changes in the types of positive allergens; | — |
Countries
China
Contacts
Public ContactJiang Chenyan
The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Outcome results
None listed